Lundbeck企业 Annual report 2005英文学习资料.pdf

《Lundbeck企业 Annual report 2005英文学习资料.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、ANNUALREPORT2005Weimprovethequalityoflifeforthosesufferingfrompsychiatricandneurologicaldisorders2005INBRIEFFinancialratiosRevenuebygeography,DKKmDKKmRevenue9,0702005GrowthShare*Researchanddevelopment1,782Europa5,07611%55%Profitfromoperations2,170USA2,618-23%29%Netprofitfortheyear1,5

2、89InternationalMarkets1,1433%13%Otherrevenue232-63%3%DKKpershareEarningspershare(EPS)7.11*ShareofconsolidatedrevenueDividendpershare2.10�������������������������������100%focusonCNS��Lundbeckistheonlyfullyintegratedpharmaceuticalcompanyinthe���������worldfocusingexclusivelyontreating

3、diseasesofthecentralnervous�����������������������system–CNS.Duringthepastfouryears,Lundbeckhaslaunchedfour������������������������������newandinnovativepharmaceuticals.�������������SalesoftheGroup’snewpharmaceuticals–Cipralex®/Lexapro®,Ebixa®andAzilect®represented69%ofrevenuein2005.

4、Atthebeginningof2006,LundbecklaunchedSerdolect®.������Lundbeck’spharmaceuticalsCipralex®/Lexapro®(escitalopram)fortheEbixa®(memantine)forthetreatmentofphreniabothreceivedmarketingapprovaltreatmentofdepressionandanxietyhasAlzheimer’sdiseasewaslaunchedin2002.during2005.Azilect®waslaunc

5、hedinthebeenapprovedin82countries,andattheMemantinewasthesecond-mostprescribedfirstcountryinEuropeinJune,whileendof2005itwasthesecond-mostpre-pharmaceuticalforthetreatmentofAlzheimer’sSerdolect®waslaunchedinthefirstmarketscribedantidepressantintheUSmarket,diseaseinEuropein2005.inEuro

6、peatthebeginningof2006.whilethemarketshareheldbyCipralex®inEuropeattheendof2005hadclimbedtoAzilect®(rasagiline)forthetreatmentofSeealistofLundbeck’spharmaceuticalson9.9%ofthetotalantidepressantsmarketinParkinson’sdiseaseandSerdolect®page26.termsofvalue.(sertindole)forthetreatmentofsc

7、hizo-DevelopmentpipelineIn2005,Lundbeckpursuedactivitiesforthe•SchizophreniaandpsychoticdisordersLundbeckintendstomaintainitshighlevelclinicaldevelopmentofpharmaceuticalsto(bifeprunox,Lu31-130)ofR&Dinvestments.treat:•Parkinson’sdisease(CEP1347-discontinued)Seethesectiononthedevelopme

8、ntofnew•Depr